Shi Sheng-Mei, Wen Yan-Li, Hou Hai-Bin, Liu Hai-Xia
Department of Gastroenterology.
Department of Orthopedics, Yanan University Affiliated Hospital, Yan'an.
Medicine (Baltimore). 2019 Mar;98(9):e14723. doi: 10.1097/MD.0000000000014723.
Irritable bowel syndrome (IBS) is a prevalent and debilitating condition for patients who experience this disorder. Clinical researches indicate that vitamin D (VD) can help relief the symptoms of IBS. However, no systematic review has addressed this issue yet. Thus, this systematic review aims to investigate the effectiveness and safety of VD for patients with IBS.
We will retrieve the following databases for randomized controlled trials to assess the effectiveness and safety of VD for patients with IBS: Cochrane Library, EMBASE, MEDICINE, Web of Science, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. Each database will be retrieved from its inception to January 31, 2019. Two researchers will independently selection studies, extract data and assess methodological quality. RevMan 5.3 software will be used to pool the data, and carry out the meta-analysis if it is possible.
This systematic review will evaluate the effectiveness and safety of VD for patients with IBS. The primary outcomes include stool frequency and abdominal pain. The secondary outcomes consist of stool status, quality of life, and adverse effects.
The findings of this systematic review may provide the existing evidence on the effectiveness and safety of VD for patients with IBS.
This systematic review will not require ethical approval, because all data will be extracted from the published literature. The findings of this study will be disseminated at peer-reviewed journals.PROSPERO registration number: PROSPERO CRD42019122641.
肠易激综合征(IBS)是一种常见且使患者衰弱的疾病。临床研究表明,维生素D(VD)有助于缓解IBS症状。然而,尚无系统评价涉及此问题。因此,本系统评价旨在研究VD治疗IBS患者的有效性和安全性。
我们将检索以下数据库以获取随机对照试验,以评估VD治疗IBS患者的有效性和安全性:考克兰图书馆、EMBASE、MEDICINE、科学网、补充与替代医学数据库、中国生物医学文献数据库和中国知网。每个数据库将从其创建至2019年1月31日进行检索。两名研究人员将独立选择研究、提取数据并评估方法学质量。将使用RevMan 5.3软件汇总数据,并在可能的情况下进行荟萃分析。
本系统评价将评估VD治疗IBS患者的有效性和安全性。主要结局包括排便频率和腹痛。次要结局包括大便状态、生活质量和不良反应。
本系统评价的结果可能为VD治疗IBS患者的有效性和安全性提供现有证据。
本系统评价无需伦理批准,因为所有数据将从已发表的文献中提取。本研究的结果将在同行评审期刊上发表。
PROSPERO CRD42019122641。